北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (5): 806-811. doi: 10.3969/j.issn.1671-167X.2016.05.010

• 论著 • 上一篇    下一篇

T3N0M0期肾细胞癌患者预后相关因素分析:单中心182例患者回顾性研究

彭鼎*,李学松*,张崔建△,杨恺惟,唐琦,张雷,余霄腾,何志嵩,周利群△   

  1. (北京大学第一医院泌尿外科,北京大学泌尿外科研究所,国家泌尿、男性生殖系肿瘤诊治中心,北京100034)
  • 出版日期:2016-10-18 发布日期:2016-10-18
  • 通讯作者: 张崔建,周利群 E-mail:surgeon_zhang@126.com, zhouliqunmail@sina.com

Prognostic factors of patients with T3N0M0 renal cell carcinoma: a single-center retrospective study of 182 patients

PENG Ding*, LI Xue-song*, ZHANG Cui-jian△, YANG Kai-wei, TANG Qi, ZHANG Lei, YU Xiao-teng, HE Zhi-song, ZHOU Li-qun△   

  1. (Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; National Urological Cancer Center; Beijing 100034, China)
  • Online:2016-10-18 Published:2016-10-18
  • Contact: ZHANG Cui-jian,ZHOU Li-qun E-mail:surgeon_zhang@126.com, zhouliqunmail@sina.com

摘要:

目的:研究影响T3N0M0期肾细胞癌患者肿瘤学预后的临床及实验室检查因素。方法:回顾性分析2007年至2012年于北京大学第一医院行手术治疗的T3N0M0肾细胞癌患者的临床资料、实验室检查结果及随访数据。应用Kaplan-Meier法计算生存率,Log-rank方法进行单因素分析,对单因素分析中显著相关的变量采用Cox模型进行多因素生存分析。结果:共182例T3N0M0肾细胞癌患者纳入研究,其中男性患者126例(69.23%),女性患者56例(30.77%)。患者平均年龄为(56.75±12.45)岁,中位随访时间48个月(3~99个月),末次随访时共有50例(27.47%)患者死亡,59例患者(32.42%)复发。患者的5年肿瘤特异性生存率为68.30% (95% CI: 60.16%~75.84%),5年无复发生存率为60.70%(95% CI: 53.16%~68.84%)。多因素分析发现,糖尿病(HR=2.434, 95% CI:1.243~4.769, P=0.010)、术前低白蛋白血症(HR=2.188, 95% CI:1.074~1.074, P=0.031)及贫血(HR=3.320, 95% CI:1.839~5.991, P<0.001)是T3N0M0肾细胞癌患者术后肿瘤特异生存的独立危险因素,更高的Fuhrman分级(HR=2.552, 95% CI:1.433~4.545, P=0.001)、术前贫血(HR=2.535, 95% CI:1.497~4.293, P=0.001)是T3N0M0肾细胞癌患者术后复发的独立危险因素。结论:糖尿病、术前低白蛋白血症、贫血是T3N0M0肾细胞癌患者术后生存的独立危险因素;高Fuhrman分级、贫血是T3N0M0肾细胞癌患者术后复发的独立危险因素。

关键词: 肾肿瘤, 癌, 肾细胞, 治疗结果, 肾切除术

Abstract:

Objective: To evaluate the impacts of clinical, pathological, and laboratory factors on oncological outcomes of patients with T3N0M0 renal cell carcinoma. Methods: The clinical data, laboratory exam results, and follow-up outcomes of 182 patients with T3N0M0 renal cell carcinoma who underwent nephrectomy from 2007 to 2012 in Peking University First Hospital were retrospectively collected. The 5-year cancer-specific survival and 5-year recurrence-free survival of all the patients were calculated using Kaplan-Meier method, and the statistical significance between the survival curves were compared using the Logrank test. Variables with significant differences in the univariate analysis were subjected to the multivariate analysis by Cox regression model. All the comparisons were conducted using two-tailed test and P<0.05 was considered statistically significant. Results: A total of 182 patients were included in this study. Of all the 182 patients, 126 were male (69.23%) and 56 were female (30.77%). The mean age was (56.75±12.45) years. The median follow-up time was 48 months (3-99 months). At the end of the follow-up, 50 patients (27.47%) died due to the disease after a median of 29.74 months and 59 patients (32.42%) had tumor recurrence after a median of 22.12 months. The 5-year cancer-specific survival of all patients was 68.30% (95% CI: 60.16%-75.84%); the 5-year recurrencefree survival was 60.70% (95% CI: 53.16%-68.84%). In the univariate analysis, diabetes mellitus, tumor invasion status, Fuhrman grade, serum album, serum cholestenone, anemia, and neutrophils percentage were associated with the cancer-specific survival and Fuhrman grade, serum album and anemia were associated with the recurrence-free survival. Variables with significant differences on univariate analysis were included in Cox multivariate regression analysis. Multivariate Logistic regression analysis showed that diabetes mellitus (HR=2.434, 95% CI: 1.243-4.769, P=0.010), hypoalbuminemia (HR=2.188, 95% CI: 1.074-1.074, P=0.031), and anemia (HR=3.320, 95% CI: 1.839-5.991, P<0.001) were independent risk factors significantly associated with cancerspecific survival; and higher Fuhrman grade (HR=2.552, 95% CI: 1.433-4.545, P=0.001), anemia (HR=2.535, 95% CI: 1.497-4.293, P=0.001) were independent factors significantly associated with recurrence-free survival. Conclusion: Diabetes mellitus, hypoalbuminemia, and anemia were independent risk factors significantly associated with cancer-specific survival of T3N0M0 renal cell carcinoma patients; higher Fuhrman grade and anemia were independent risk factors significantly associated with tumor recurrence of T3N0M0 renal cell carcinoma patients.

Key words: Kidney neoplasms, Carcinoma, renal cell, Treatment outcome, Nephrectomy

中图分类号: 

  • R737.11
[1] 黄教悌,胡菁,韩博. 治疗相关神经内分泌前列腺癌机制研究与靶向治疗新进展[J]. 北京大学学报(医学版), 2024, 56(4): 557-561.
[2] 张树栋,谢睿扬. 机器人手术时代的肾癌合并腔静脉瘤栓治疗策略[J]. 北京大学学报(医学版), 2024, 56(4): 562-564.
[3] 邢念增,王明帅,杨飞亚,尹路,韩苏军. 前列腺免活检创新理念的临床实践及其应用前景[J]. 北京大学学报(医学版), 2024, 56(4): 565-566.
[4] 颜野,李小龙,夏海缀,朱学华,张羽婷,张帆,刘可,刘承,马潞林. 前列腺癌根治术后远期膀胱过度活动症的危险因素[J]. 北京大学学报(医学版), 2024, 56(4): 589-593.
[5] 于书慧,韩佳凝,钟丽君,陈聪语,肖云翔,黄燕波,杨洋,车新艳. 术前盆底肌电生理参数对前列腺癌根治性切除术后早期尿失禁的预测价值[J]. 北京大学学报(医学版), 2024, 56(4): 594-599.
[6] 刘帅,刘磊,刘茁,张帆,马潞林,田晓军,侯小飞,王国良,赵磊,张树栋. 伴静脉癌栓的肾上腺皮质癌的临床治疗及预后[J]. 北京大学学报(医学版), 2024, 56(4): 624-630.
[7] 杨捷,冯杰莉,张树栋,马潞林,郑清. 经食管超声心动图在肾切除术联合Mayo Ⅲ~Ⅳ级静脉瘤栓取栓术不同手术方式中的临床作用[J]. 北京大学学报(医学版), 2024, 56(4): 631-635.
[8] 王滨帅,邱敏,张前进,田茂锋,刘磊,王国良,陆敏,田晓军,张树栋. 6例肾尤文肉瘤伴静脉瘤栓的诊治[J]. 北京大学学报(医学版), 2024, 56(4): 636-639.
[9] 虞乐,邓绍晖,张帆,颜野,叶剑飞,张树栋. 具有低度恶性潜能的多房囊性肾肿瘤的临床病理特征及预后[J]. 北京大学学报(医学版), 2024, 56(4): 661-666.
[10] 舒帆,郝一昌,张展奕,邓绍晖,张洪宪,刘磊,王国良,田晓军,赵磊,马潞林,张树栋. 肾部分切除术治疗囊性肾癌的功能学和肿瘤学结果:单中心回顾性研究[J]. 北京大学学报(医学版), 2024, 56(4): 667-672.
[11] 周泽臻,邓绍晖,颜野,张帆,郝一昌,葛力源,张洪宪,王国良,张树栋. 非转移性T3a肾细胞癌患者3年肿瘤特异性生存期预测[J]. 北京大学学报(医学版), 2024, 56(4): 673-679.
[12] 李文菁,张保宙,李恒,赖良鹏,杜辉,孙宁,龚晓峰,李莹,王岩,武勇. 胫距跟融合治疗终末期踝和后足病变的中短期临床结果[J]. 北京大学学报(医学版), 2024, 56(2): 299-306.
[13] 苏俊琪,王晓颖,孙志强. 舌鳞状细胞癌根治性切除术后患者预后预测列线图的构建与验证[J]. 北京大学学报(医学版), 2024, 56(1): 120-130.
[14] 邹雪,白小娟,张丽卿. 艾拉莫德联合托法替布治疗难治性中重度类风湿关节炎的疗效[J]. 北京大学学报(医学版), 2023, 55(6): 1013-1021.
[15] 薛蔚,董樑,钱宏阳,费笑晨. 前列腺癌新辅助治疗与辅助治疗的现状及进展[J]. 北京大学学报(医学版), 2023, 55(5): 775-780.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!